drugset / Trial / NCT00137397

A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder

NCT00137397

Phase 4 Completed 80 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound. This will help doctors to understand whether there is a link between changes in the thickness of the bladder wall and progression of symptoms.

Timeline

Start
2004-11
Primary completion
Completion
2006-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolterodine Small molecule

Indications